European Stocks Mixed Friday Amid COVID-19 Vaccine-Related News
12:14 PM EST, 02/05/2021 (MT Newswires) -- European stocks were mixed Friday as the region continues to battle the ongoing COVID-19 pandemic despite delays in vaccine rollout.
The European Stoxx 600 was flat, while the German DAX was barely changed. The FTSE 100 declined 0.2% and the Swiss Market Index retreated 1%. The French CAC 40 added 0.9%.
In the UK, the Medicines and Healthcare products Regulatory Agency said an analysis of data on all approved COVID-19 vaccines confirmed their strict regulatory standards for safety. The regulator said the majority of the side effects are mild and short-lasting.
The UK is also planning to "rapidly develop" new COVID-19 vaccines with German pharmaceutical firm CureVac that will tackle new variants and will use the messenger RNA technology.
Meanwhile, AstraZeneca's (AZN.L) COVID-19 vaccine, which it co-developed with the University of Oxford, was found effective against the variant detected in the UK regions of Kent and the South East, media outlets reported.
On the data front, Germany's industrial production is expected to continue rising in the coming months after manufacturing orders in December 2020 fell 1.9%, the first decline following a seven-month climb, Commerzbank said.
Among individual stocks, Aggreko (AGK.L) rose 33% after confirming a media report that it is in talks with TDR Capital and I Squared Capital (US) in connection with the consortium's proposed takeover offer of GBP8.80 ($12.1) per share in cash.